All data are based on the daily closing price as of July 22, 2024
t

TTY Biopharm

4105.TWO
2.28 USD
-0.02
-0.87%

Overview

Last close
2.28 usd
Market cap
567.01M usd
52 week high
2.70 usd
52 week low
2.28 usd
Target price
2.28 usd

Valuation

P/E
16.0638
Forward P/E
16.1551
Price/Sales
3.5318
Price/Book Value
3.2727
Enterprise Value
545.73M usd
EV/Revenue
3.368
EV/EBITDA
11.1993

Key financials

Revenue TTM
170.86M usd
Gross Profit TTM
91.98M usd
EBITDA TTM
49.59M usd
Earnings per Share
0.14 usd
Dividend
0.11 usd
Total assets
315.47M usd
Net debt
N/A usd

About

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments. The company provides anti-infection drugs under the Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax names for anti-infection and flu. In addition, it offers healthcare related drugs under the Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin names for digest system, osteoporosis, and metabolism. Further, the company engages in the selling functional foods; and import and export trading and investment activities. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.
  • Symbol
    4105.TWO
  • Exchange
    TWO
  • Isin
    TW0004105002
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Yung-Min Chiang
  • Headquarter
    Taipei
  • Web site
    https://www.tty.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top